NCT04865497已完成2 期
A Randomized, Blinded, Single-center, Parallel Controlled , Phase Ⅱ Clinical Trial to Evaluate Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged From 3 Months to 5 Years Old
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,050
- 试验地点
- 1
- 主要终点
- incidence of adverse events during 30 days
研究概览
简要总结
The purpose of this study is to evaluate immunogenicity and safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 3 Months 至 5 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Health infants and children aged from 3 months to 5 years old.
- •Subject or legal representative who consent and has signed written informed consent.
- •Subject and parent/guardian who is able to comply with all study procedures.
- •Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination.
- •Subject who haven't immuned with diarrhea vaccination,3-11 months health infants who haven't immuned with Haemophilus b Conjugate vaccination,or had a history of Hib vaccination before the age of 1 but no history of vaccination after 1 year of age,and the interval between the day of the enrollment and the previous dose is more than one month.
- •Axillary temperature ≤37.0 ℃.
排除标准
- •Febrile illness (temperature ≥ 38°C) in the 3 days or in the acute phase of the disease / active period.
- •Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days.
- •Subject who are allergic to tetanus toxoid.
- •Allergic history after vaccination.
- •Immunodeficiency diseases patients (such as perianal abscess suggests that there may be immunodeficiency in infants and young children) who administered with immunosuppressive agents (≥14 days).
- •Subject who are suffering from serious chronic diseases, cardiovascular disease,liver or kidney disease.
- •Subject with congenital malformations, drug allergies, convulsions, epilepsy, history of craniocerebral trauma, encephalopathy and psychosis, or family history.
- •Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication.
- •Children with abnormal labor（pregnancy week<37w,>42w）,birth weight (<2500g,>4000g), asphyxia rescue history(Only applicable to 3-5 months old group).
- •Subject who plan to participate in or is in any other drug clinical trial.
- •Any condition that, in the judgment of investigator, may affect trial assessment.
结局指标
主要结局
incidence of adverse events during 30 days
时间窗: 30 day after each vaccination
Occurrence of adverse events during a 30 day follow-up period after each vaccination
Antibody positive rate
时间窗: 30 day after each vaccination
Percentage of participants with seroresponse to each vaccination
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 YearsShigellosisDysenteryNCT05156528Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd21,000
已完成
1 期
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 MonthsDysentery, BacillaryDysenteryNCT03561181Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd180
已完成
1 期
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19SARS-CoV-2 InfectionNCT04784767U.S. Army Medical Research and Development Command29
已完成
2 期
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeNCT05630846GlaxoSmithKline801
已完成
1 期
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)Pneumococcal InfectionNCT04665050Merck Sharp & Dohme LLC102